Key result
Levetiracetam can induce torsades de pointes (TDP), evidenced by a 59-year-old female requiring multiple cardioversions after its administration.
Why the study?
Levetiracetam has a highly favorable safety profile, and torsades de pointes following its administration is exceptionally rare, with no documented cases in the Indian subcontinent.
Answers are grounded in this paper and cite their sources.
Highlights a rare but severe adverse event of torsades de pointes associated with levetiracetam use.
Torsades de pointes (TDP) is a result of prolonged QTc interval, which may be due to congenital and acquired factors. Levetiracetam is a commonly prescribed anti-epileptic drug and has a highly favorable safety profile. Here, we report the unique occurrence of TDPs leading to multiple electric cardioversions in a 59-year-old female following the administration of levetiracetam. As far as we know, there is only very few previous documented case of TDPs occurring after levetiracetam and none in the Indian subcontinent.
No takes yet. Share an insight, caveat, or question.
Modi et al. (2026) studied this question. Levetiracetam can induce torsades de pointes (TDP), evidenced by a 59-year-old female requiring multiple cardioversions after its administration.
Synapse has enriched 10 related papers. Consider them for comparative context: